Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (691-700 of 759) with videos related to

Pageof 76
Sort By:
Blood Cancer Journal|December 14, 2020
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patientsAlissa Visram, Abdullah S Al Saleh, Harsh Parmar, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology|July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantationCihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
Pageof 76

Showing results (691-700 of 759) with videos related to

Sort By:
Pageof 76
Blood Cancer Journal|December 14, 2020
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patientsAlissa Visram, Abdullah S Al Saleh, Harsh Parmar, et al.
Blood Advances|December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman diseaseFrits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
JAMA Oncology|August 1, 2024
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisEli Muchtar, Brendan Wisniowski, Susan Geyer, et al.
Blood Advances|February 14, 2025
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registrySheila K Pierson, Joshua D Brandstadter, Drew A Torigian, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
American Journal of Hematology|July 4, 2020
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantationCihan Heybeli, Meera Sridharan, Hassan B Alkhateeb, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Circulation. Cardiovascular Imaging|May 13, 2018
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain AmyloidosisPaolo Milani, Angela Dispenzieri, Christopher G Scott, et al.
Pageof 76